We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) ended the recent trading session at $1,146.90, demonstrating a -2.73% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
The stock of drugmaker has risen by 7.33% in the past month, leading the Medical sector's gain of 6.06% and the S&P 500's gain of 0.55%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on August 5, 2026. In that report, analysts expect Eli Lilly to post earnings of $7.47 per share. This would mark year-over-year growth of 18.38%. In the meantime, our current consensus estimate forecasts the revenue to be $20.26 billion, indicating a 30.24% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $34.55 per share and revenue of $85.78 billion. These totals would mark changes of +42.71% and +31.6%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.52% lower. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 34.13. This indicates a premium in contrast to its industry's Forward P/E of 16.49.
We can additionally observe that LLY currently boasts a PEG ratio of 1.48. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.65.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 231, positioning it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY - Free Report) ended the recent trading session at $1,146.90, demonstrating a -2.73% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
The stock of drugmaker has risen by 7.33% in the past month, leading the Medical sector's gain of 6.06% and the S&P 500's gain of 0.55%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on August 5, 2026. In that report, analysts expect Eli Lilly to post earnings of $7.47 per share. This would mark year-over-year growth of 18.38%. In the meantime, our current consensus estimate forecasts the revenue to be $20.26 billion, indicating a 30.24% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $34.55 per share and revenue of $85.78 billion. These totals would mark changes of +42.71% and +31.6%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.52% lower. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 34.13. This indicates a premium in contrast to its industry's Forward P/E of 16.49.
We can additionally observe that LLY currently boasts a PEG ratio of 1.48. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.65.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 231, positioning it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.